• Mashup Score: 4
    Novel therapies to know for ASCVD prevention in 2021 and beyond - 4 year(s) ago

    Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      ICYMI: "Data support a 'lower is better' paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing progressive [ASCVD] event reduction even at LDL levels well below 30 mg/dL." @SethShayMartin @rblument1 @TLeucker @GarimaVSharmaMD @mchilazi https://t.co/DfCL68gQVg

  • Mashup Score: 9
    Novel therapies to know for ASCVD prevention in 2021 and beyond - 4 year(s) ago

    Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      In this commentary experts review the mechanisms, safety profiles and availability for clinical use of novel therapies for #ASCVD prevention @SethShayMartin @HopkinsMedicine @CiccaroneCenter @rblument1 @TLeucker @GarimaVSharmaMD @mchilazi #CardioTwitter https://t.co/M589Xz8LgU

  • Mashup Score: 0
    Genetic Testing for Managing Dyslipidemia - American College of Cardiology - 4 year(s) ago

    The link between elevated serum cholesterol, triglyceride, and lipoprotein levels and increased atherosclerotic cardiovascular disease (ASCVD) risk is well established.1 Patients with significantly elevated lipoprotein or triglyceride levels, or a family history of premature ASCVD, may warrant additional testing to screen for genetically inherited dyslipidemias,…

    Source: American College of Cardiology
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rblument1
      rblument1

      Genetic Testing for Managing Dyslipidemia - ACC led by @ChloeDuvall9 @GucukEsra @TLeucker @CiccaroneCenter @hopkinsheart @OslerResidency @sanjayvdesai #🥍🏏⛳️🎾 🏀🏃‍♀️🏊🏽🚣‍♀️🔨 https://t.co/Qhfa1xYCdq

  • Mashup Score: 2
    Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period | Circulation - 5 year(s) ago

    Elevated low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk of adverse ischemic outcomes in the early post–acute coronary syndrome (ACS) period.1 Achieving American Heart Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology (ESC) recommendations for secondary prevention in high-risk patients such as those with ACS, however, is not…

    Source: www.ahajournals.org
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CircAHA
      CircAHA

      In EVACS trial, evolocumab significantly reduces atherogenic lipoproteins during the peri- & early post-infarction period in NSTEMI. Read more: https://t.co/0vLleVTOyn @HopkinsMedicine @hopkinsheart @TLeucker @GGerstenblith @DoctorLatina #AHAJournals https://t.co/6DjNbHS8mL

  • Mashup Score: 10
    Evolocumab after ACS may lower LDL within 24 hours - 5 year(s) ago

    Patients who were given evolocumab shortly after ACS had rapid and significant LDL reductions in 24 hours, researchers found in the EVACS trial.“The implications for clinical practice are limited to the rapid reduction in atherogenic lipoproteins in the ACS patient population,” Thorsten M. Leucker, MD, PhD, assistant professor of medicine in the division of cardiology, director of

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      Patients who were given evolocumab shortly after ACS had rapid and significant LDL reductions in 24 hours, researchers found in the EVACS trial @TLeucker @HopkinsMedicine @CiccaroneCenter @CircAHA #CardioTwitter https://t.co/7RxKCeuhcb